Defining lipidomic biomarkers of the interactions between Western diet and liver health using mass spectrometry imaging
Defining lipidomic biomarkers of the interactions between Western diet and liver health using mass spectrometry imaging
批准号:
2665838
负责人:
金额:
$0.0万
依托单位:
依托单位国家:
英国
项目类别:
Studentship
财政年份:
2021
资助国家:
英国
项目状态:
未结题
起止时间:
2021 至 --
中文摘要
生活方式因素影响健康老龄化。饮食选择改变了对许多疾病的易感性。低脂肪的地中海饮食是抗氧化剂,被认为对健康有益,而高脂肪的“西方饮食”则会导致负面的健康后果。体重指数在全球范围内都在增加,这与许多疾病的风险增加有关,包括糖尿病和非酒精性脂肪性肝病(NAFLD),但个体风险是可变的。当受到高脂肪饮食的挑战时,身体的反应是调整脂肪储存量,并将脂肪“异位”储存在肝脏中。这种健康的适应性反应最初是无害的。然而,超过一定的水平,在某些个体中,代谢灵活性被超过,过多的异位脂肪会触发进行性肝纤维化、肝硬变和肝细胞癌。需要生物标志物来区分健康和不健康的饮食适应,以提高高危个体的健康寿命。代谢组学提供了个人生化状态的指纹;脂质组学是一个子领域,对调节新陈代谢和炎症的内源性脂质进行分类。脂质组学最常在血液中进行,很容易取样,对健康筛查很有用。然而,循环中的脂小体可能不反映组织。当肝脏健康下降时,健康组织和高危组织共存时,就会发生地带性变化。因此,肝脏脂肪体征必须在空间上描述。这个学生将开发质谱仪成像(MSI)来空间分析肝脏中的脂类,并确定它们对饮食的反应。特别是,溶血磷脂酰胆碱在自体趋化素酶作用下过度转化为其酸性代谢物将被详细研究。假设脂肪含量的不同会不同地影响肝脏的脂体。MSI揭示的脂体学特征将确定评估肝脏健康和疾病的途径,并确定可通过生活方式或药物进行治疗修改的标志物。项目计划最初,学生将建立MSI以从小鼠和人类的肝脏切片中提取脂质样本。LC-MS/MS还将用于测量血浆中的关键血脂。接下来,我们将研究代表健康动物的小鼠模型的肝脏脂肪组,并通过改变脂肪/碳水化合物含量来研究肥胖饮食的影响。将开发图像分析方法,以共同定位组织学和脂体学特征,旨在开发预测模型,以识别危险区域。随着饮食时间的延长,脂类的变化将与疾病阶段(健康与脂肪/炎症/纤维化肝病)进行比较和关联,以对生物标记物进行分层。小鼠模型的研究结果将被转化为来自NHS洛锡安生物资源中心的人类肝脏样本,并证明在小鼠模型中使用自体趋化蛋白抑制剂建立的可逆性原理研究培训学生将接受广泛的跨学科培训,包括:a)使用动物模型和人类的肝组织进行体内和体外研究;b)通过生物分析MS进行脂类组学研究;c)脂组数据集的多元统计分析,包括与在线数据库的接口;(D)组织学特征的联合登记和图像分析。研究将在女王医学研究所内资金充足的实验室进行,这些实验室为拟议的实验配备了完整的设备。Khan,Andrew(2019)MSI of Lipoid,当代和新兴技术在脂类组学中,皇家化学学会,伦敦,出版社。Iredale,Pellicoro,Flowfield(2017)肝脏纤维化:了解双向伤口修复的动力学,为标记物和治疗的设计提供信息。Dig Dis 2017;35:310-313.Cobice等人(2017)对11β-HSD1的动力学和药效学效应进行了定量研究.
英文摘要
Lifestyle factors influence healthy ageing. Dietary choices modify susceptibility to many diseases. The low-fat Mediterranean diet is anti-oxidant and believed beneficial for health, whereas high-fat "Western diet" associates with negative health outcomes. Body mass index is increasing worldwide, linked to increased risk of many diseases, including diabetes and non-alcoholic fatty liver disease (NAFLD), but individual risk is variable. When challenged with a fatty diet, the body responds by adjusting adipose depot volume and by storing fat "ectopically" e.g. in liver. This healthy, adaptive response is initially not harmful. However, beyond a certain level and in some individuals, metabolic flexibility is exceeded and too much ectopic fat triggers progressive liver fibrosis, cirrhosis and hepatocellular carcinoma. Biomarkers are needed to differentiate healthy vs unhealthy dietary adaptation to improve the healthspan of at-risk individuals. Metabolomics provides a fingerprint of personal biochemical status; lipidomics is a sub-field, categorising endogenous lipids regulating metabolism and inflammation. Lipidomics is most commonly conducted in blood, easy to sample and useful for health screening. However, the circulating lipidome may not reflect tissues. When liver health declines, zonal changes occur with healthy and at-risk tissue co-existing. Therefore, the hepatic lipidomic signature must be described spatially. This studentship will develop mass spectrometry imaging (MSI) to spatially profile lipids in liver and define their response to diet. In particular, excessive conversion of lysophosphatidyl cholines to their acidic metabolites by the enzyme autotaxin will be studied in detail.HypothesisDiets varying in fat content differentially affect the hepatic lipidome. The lipidomic signature revealed by MSI will identify pathways to assess liver health and disease and identify markers amenable to therapeutic modification either by lifestyle or drugs.Project PlanInitially, the student will establish MSI to sample lipids from liver sections of mouse and human. LC-MS/MS will also be deployed to measure key lipids in plasma. The profile of lipids will be described and species identified through alignment with lipidomic databases e.g. Lipidmaps.Next, we will study the hepatic lipidome of mouse models representative of healthy animals and study the effect of an obesogenic diet by varying the fat/carbohydrate content. Image analysis methods for co-localising histological and lipidomic features will be developed, aiming to develop predictive models to identify regions at risk. The changes in the lipidome with the duration of diet will be compared and correlated with stages of disease (healthy versus fatty/inflamed/fibrotic liver disease) to stratify biomarkers. Findings in mouse models will be translated to human liver samples from the NHS Lothian BioResource and proof of principle of reversibility established using inhibitors of autotaxin in murine modelsResearch TrainingThe student will receive interdisciplinary training in a broad range of methods including: a) in vivo and in vitro studies using liver tissue from animal models and humans; b) lipidomics by bioanalytical MS; c) multivariate statistical analysis of lipidomic datasets, involving interfacing with online databases; (d) co-registration and image analysis of histological features. Studies will be conducted in well-funded laboratories within the Queen's Medical Research Institute which are fully equipped for the proposed experiments.Khan, Andrew (2019) MSI of lipids, Current and emerging technologies in lipidomics, Royal Society of Chemistry, London, In Press.Iredale, Pellicoro, Fallowfield (2017) Liver Fibrosis: Understanding the dynamics of bidirectional wound repair to inform the design of markers and therapies. Dig Dis 2017;35:310-313.Cobice et al (2017) Quantification of 11beta-HSD1 kinetics and pharmacodynamic effects of inhibitors in br...
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金